Notice ID: 7358dc5dd5674efb9fad87e2c9301007Combined Synopsis/SolicitationArchived
6515--Cranial instrument SET
Archived on July 30, 2026. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 9:00 AM PDT
- Posted
- July 23, 2026
- Notice type
- Combined Synopsis/Solicitation
Notice details
- Office
- 262-NETWORK CONTRACT OFFICE 22 (36C262)
- Place of performance
- Department of Veterans Affairs VA San Diego Healthcare System, San Diego, CA, 92161
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- 36C26226Q1223
- Notice ID
- 7358dc5dd5674efb9fad87e2c9301007
Description
See attached.
Award Overview
Possible prior contract
Inferred, not confirmedInferred, not confirmed. Matched by agency, NAICS, place of performance and end-date proximity. This is a candidate, not the contractor of record.
Contract end date
Jun 30, 2027
NAICS
339112
Agency
Department of Veterans Affairs
Dollar amounts are not shown for inferred matches because the link is heuristic. Open the award below to check it.
Contacts
Contracting Officer
Primary Contact
Documents
Files (2)
Links (1)
- Agency Websitewww.va.govPosted
Lifecycle
- 3Version 3Combined Synopsis/SolicitationArchivedCurrent
6515--Cranial instrument SET
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
92% | Awarded | Open | |
See attached solicitation for METRx Instruments OR Equal. This is a brand name or equal solicitation with small business set aside IAW RFO Part 12. Please see Addendum to 52.212-1 Instructions to Offerors and 52.212-2 Evaluation for important information on submitting your quote and how quotes will be evaluated. | 88% | Combined Synopsis | 11/13/2026 |
6515--541-26-3-250-0303 - Olympus BX43 Pathology Microscope Brand Name Only Small Business Set-Aside Combined Synopsis/Solicitation Notice *= Required Field Combined Synopsis/Solicitation Notice DESCRIPTION This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Federal Acquisition Regulation (FAR) subpart 12.6, Streamlined Procedures for Evaluation and Solicitation for Commercial Items, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested, and a written solicitation document will not be issued. This solicitation is issued as an RFQ. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2023-01. This solicitation is a Small Business set-aside. The associated North American Industrial Classification System (NAICS) code for this procurement is 339112. The FSC/PSC is 6515. The NCO 10 for Cleveland VA Medical Center is seeking to purchase the Olympus BX Microscope for the Cytology Department. This solicitation closes on September 25, 2026 @ 13:00 AM. Quotes should be submitted to Kevin Peeples kevin.peeples@va.gov Please reference 36C25026Q1066 1. Contracting Officer s Representative (COR NA 2. CONTRACT TITLE: BX43-1-3 Cytology Microscopes 3. BACKGROUND The Department of Veterans Affairs Northeast Ohio Healthcare System (VANEOHS) has an immediate requirement for the procurement of two (2) brand name Evident (formerly Olympus) BX43-1-3 cytology microscopes, inclusive of the True Color LED light source compatible with BX43F, BX46F, and BX63F platforms, and all required Original Equipment Manufacturer (OEM) components and accessories necessary for full clinical activation and use. The requested microscopes are additional units to the currently deployed Evident BX-series microscopes within the Cytology Section of Pathology & Laboratory Management Services (PALMS). The laboratory s diagnostic workflows, digital imaging systems, standardized operating procedures, educational protocols, and preventative maintenance programs are fully based upon the Evident BX-series platform. The Cytology laboratory s diagnostic workflows, digital imaging systems, standardized operating procedures, educational platforms, and preventative maintenance programs are built upon the BX-series architecture. The Cytology Section performs high-resolution visualization and evaluation of: Cellular morphology Cytological abnormalities Microbiological organisms Inflammatory processes Neoplastic pathologies These diagnostic evaluations are mission-critical to accurate, timely, and actionable patient diagnoses. This acquisition is required to maintain full operational capacity, mitigate diagnostic backlog, maximize utilization of existing Government-owned assets, and ensure uninterrupted cytopathology services. 4. SCOPE The Contractor shall provide two (2) new, current production BX43-1-3 microscopes, inclusive of the True Color LED light source and all requested and associated OEM components, accessories, modules, assemblies, and consumables required for immediate clinical deployment within the Cytology Section. The Contractor shall provide on-site installation, configuration, and operational verification of all microscopes and associated OEM components at the Louis Stokes Cleveland VA Medical Center, Pathology & Laboratory Management Services Cytology Section. Installation shall include full assembly, alignment of optical components, calibration of the illumination system, verification of mechanical stage functionality, confirmation of imaging integration (if applicable), and validation of overall system performance for clinical diagnostic use. All equipment shall be fully operational and ready for immediate patient care application upon completion of installation. Any deficiencies identified during installation or inspection shall be corrected by the Contractor at no additional cost to the Government prior to final acceptance. The microscopes and components shall meet or exceed the following operational, optical, interoperability, and performance requirements: Optical and Imaging Performance: UIS2 infinity-corrected optical system Plan Apochromat or Plan Fluorite objectives optimized for cytology applications High numerical aperture objectives suitable for oil immersion cytopathology 100x oil immersion capability Wide field number (FN 22 or greater) High-resolution visualization suitable for evaluation of cellular morphology, cytologic abnormalities, infectious organisms, and neoplastic processes OEM camera adapter compatibility for integration with existing digital imaging systems Illumination System: True Color LED light source compatible with BX43F, BX46F, and BX63F Daylight-balanced illumination to support accurate cytologic color interpretation Flicker-free, stable output LED lifespan 20,000 hours Intensity memory function Uniform illumination across full field of view Ergonomic and Mechanical Features: Ergonomic observation tube with adjustable inclination Low-position coaxial focus knobs Coarse and fine focus with tension adjustment Precision mechanical stage with fine movement control Stage inserts compatible with cytology slide preparation Configuration optimized for prolonged microscopic review Required OEM Accessories and Components: The Contractor shall provide all OEM components necessary to ensure full functionality and activation, including but not limited to: Proprietary stage inserts Light modules Camera adapters Immersion oil kits (OEM approved) Dust covers Power cords Calibration and setup materials Required mounting hardware Any additional OEM components necessary for clinical operation All components must be new, OEM-manufactured, and fully compatible with existing Evident BX-series microscopes currently deployed within the laboratory. Interoperability Requirements: The Cytology Section is standardized on the Evident BX-series microscope platform. All diagnostic workflows, imaging protocols, training materials, and maintenance programs are built upon this system. The requested microscopes are additional to the currently deployed fleet and must: Integrate seamlessly with existing BX-series equipment Maintain optical consistency across the microscope fleet Preserve manufacturer warranty protections Support existing service contracts and maintenance protocols Require no retraining due to platform change Non-OEM or alternate-brand equipment would: Disrupt standardized diagnostic workflow Introduce optical variability affecting diagnostic consistency Invalidate manufacturer warranties Require retraining of cytotechnologists and pathologists Undermine fleet uniformity and serviceability Warranty: Equipment shall include the manufacturer s standard warranty covering optical, mechanical, and illumination systems for a minimum of one (1) year. 6. Performance Monitoring The Government will monitor contractor performance to ensure compliance with all requirements outlined in this Statement of Work. Performance monitoring will include verification of timely delivery, proper installation, system functionality, completion of required training, and successful commissioning of the equipment in accordance with manufacturer specifications. Government representatives, including Pathology & Laboratory Medicine Service personnel and designated technical staff, will validate that the system operates as intended and meets operational and functional requirements prior to acceptance. Any deficiencies identified during delivery, installation, or operational verification shall be corrected by the Contractor at no additional cost to the Government. The Contractor shall coordinate all activities with the designated Government point of contact to ensure minimal disruption to laboratory operations and adherence to agreed installation schedules. 7. Security Requirements The C&A requirements do not apply, and the Security Accreditation package is not required for this SOW. 8. Government-Furnished Equipment (GFE)/Government-Furnished Information (GFI). There will be no government-Furnished equipment of information. 9. Other Pertinent Information or Special Considerations. The requested equipment shall be interoperable/usable with current workflows and technology deployed and used within the clinical atmosphere and existing BX Microscopes and associated accessories. a. Identification of Possible Follow-on Work. NA b. Identification of Potential Conflicts of Interest (COI). NA c. Identification of Non-Disclosure Requirements. NA d. Packaging, Packing and Shipping Instructions. NA e. Inspection and Acceptance Criteria. Government acceptance will occur upon: Successful installation Demonstrated operational functionality Completion of training if applicable Readiness for clinical laboratory use 10. Place of Performance. Delivery Location: Louis Stokes Cleveland VA Medical Center Pathology & Laboratory Management Services Cytology 10701 East Boulevard Cleveland, OH 44106 11. Period of Performance NA 12. Delivery Schedule. The Contractor shall deliver all required equipment and system components within ninety (90) calendar days from the date of contract award. Installation, configuration, and commissioning activities shall be coordinated with Government personnel and completed within the same 90-day period unless otherwise agreed upon in writing by the Contracting Officer. SUBMISSION Responses to this solicitation shall be submitted via email to kevin.peeples@va.gov. Telephone responses shall not be accepted. Responses must be received no later than September 25 2026, at 13:00 pm EST, (Eastern Standard Time). CLAUSES FAR Number Title Date 52.209-6 PROTECTING THE GOVERNMENT S INTEREST WHEN SUBCONTRACTING WITH CONTRACTORS DEBARRED, SUSPENDED, OR PROPOSED FOR DEBARMENT JAN 2025 52.212-4 CONTRACT TERMS AND CONDITIONS-- COMMERCIAL ITEMS NOV 2023 52.222-90 ADDRESSING DEI DISCRIMINATION BY FEDERAL CONTRACTORS APR 2026 52.232-33 PAYMENT BY ELECTRONIC FUNDS TRANSFER SYSTEM FOR AWARD MANAGEMENT OCT 2018 52.252-2 CLAUSES INCORPORATED BY REFERENCE FEB 1998 52.232-40 PROVIDING ACCELERATED PAYMENTS TO SMALL BUSINESS SUBCONTRACTORS MAR 2023 52.233-1 DISPUTES MAY 2014 52.233-3 PROTEST AFTER AWARD AUG 1996 852.219-76 852.203-70 VA NOTICE OF LIMITATIONS ON SUBCONTRACTING-CERTIFICATE OF COMPLIANCE FOR SUPPLIES AND PRODUCTS (DEVIATION) COMMERCIAL ADVERTISING JAN 2023 MAY 2018 852.232-72 ELECTRONIC SUBMISSION OF PAYMENT REQUESTS NOV 2018 852.237-70 CONTRACTOR RESPONSIBILITIES OCT 2019 PROVISIONS 52.212-1 INSTRUCTIONS TO OFFERORS-COMMERCIAL ITEMS SEP 2023 52.212-2 EVALUATION--COMMERCIAL ITEMS NOV 2021 | 75% | Combined Synopsis | 09/25/2026 |
Please see attachment for full details of the Sources Sought. | 73% | Market Research | 11/23/2026 |
Page 2 of 4 THIS REQUEST FOR INFORMATION (RFI) / SOURCES SOUGHT NOTICE IS ISSUED SOLELY FOR INFORMATION AND PLANNING PURPOSES. THIS IS NOT A SOLICITATION. SUBMISSION OF INFORMATION ABOUT PRICING, DELIVERY, THE MARKET, AND CAPABILITIES IS HIGHLY ENCOURAGED AND ALLOWED UNDER THIS RFI FOR PLANNING PURPOSES IN ACCORDANCE WITH (IAW) FAR 15.201(e). DISCLAIMER This RFI is issued solely for information and planning purposes and does not constitute a solicitation. All information received in response to this RFI that is marked as proprietary will be handled accordingly. IAW FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. SOURCES SOUGHT/RFI DESCRIPTION This is NOT a solicitation announcement. This is a Sources Sought Notice / RFI only. The purpose of this Sources Sought Notice / RFI is to gain information about potential qualified sources and their size classification relative to NAICS 339112 (size standard of 1,000 Employees). Responses to this Sources Sought Notice / RFI will be used by the Government to make appropriate acquisition decisions. After review of the responses to this Sources Sought Notice / RFI, further RFIs and/or a solicitation or other announcements may be published. The Department of Veterans Affairs (VA) is seeking sources capable of providing Avanti Polar Ganglioside GM1-SHP 25MG for the Phoenix Veterans Affairs Health Care System. The list of DRAFT characteristics is intended to be descriptive, not restrictive, of the supplies/services that are required. If your company is interested and capable of providing the required supplies/services, please provide the information indicated below. Response to this notice should include company name, address, point of contact, size of business pursuant to the following questions: (1) Submit your capabilities statement illustrating how your organization can/cannot meet the list of DRAFT/SALIENT CHARACTERISTICS/SOW requirements. For instances where your company cannot meet the DRAFT/SALIENT CHARACTERISTICS/SOW requirement(s), please explain. For instances where your company can meet the DRAFT/SALIENT CHARACTERISTICS/SOW requirement(s), please show how your company meets/exceeds each requirement. (2) Please review the list of DRAFT/SALIENT CHARACTERISTICS/SOW requirements and provide any additional feedback or suggestions. If none, please reply as N/A. (3) Please indicate the size status and representations of your business, such as but not limited to: Service-Disabled Veteran-Owned Small Business (SDVOSB), Veteran-Owned Small Business (VOSB), HUBZone, Woman Owned Small Business (WOSB), Large Business, etc. (4) Is your company considered small under the NAICS code identified in this RFI? (5) Are you the manufacturer, authorized distributor, and/or can your company provide a solution to the required supplies/services described in the list of DRAFT/SALIENT CHARACTERISTICS/SOW? (6) If you are a large business, do you have any designated/authorized distributors? If so, please provide their company name, telephone, point of contact and size status (if available). (7) If you re a small business and you are an authorized distributor/reseller for the items identified above, do you alter; assemble; modify; the items requested in any way? If you do, state how and what is altered; assembled; modified. (8) Limitations on Subcontracting: How does your business ensure compliance with the limitations on subcontracting as outlined in 13 CFR § 125.6? (9) Are the items you are identifying/providing considered Commercial of the Shelf (COTS) items as defined in FAR Part 2.101 under commercial items? (10) Non-Manufacturer Rule: If applicable, can you confirm your business complies with the Non-Manufacturer rule? Specifically, does your company: Provide a product from a small business manufacturer or processor? Not exceed 500 employees? Primarily engage in the retail or wholesale trade and normally sell the type of item being supplied? Take ownership or possession of the item(s) with its personnel, equipment or facilities in a manner consistent with industry practice? (11) What is your lead time to deliver a single unit with all components? Is there scale in lead time with greater quantities? Please elaborate. (12) What is estimated life span of your solution? What support/services does that entail? (13) Does your proposed equipment have FDA clearance? Please specify what FDA clearance(s) have been obtained. (14) Does your organization offer a leasing solution? Please elaborate. (15) Does your company have a Federal Supply Schedule (FSS) GSA/NAC/SAC/BPA/NASA SEWP or any other Federal Government contract? If so, please provide the contract number(s). (16) If you are an FSS GSA/NAC/SAC/BPA/NASA SEWP or any other Federal Government contract holder, are all the items/solutions you are providing information about available on your schedule/contract? Please state if all or some items are available on the contract. (17) General pricing of your products/solution is encouraged. Pricing will be used for the purpose of market research only. It will not be used to evaluate for any type of award. (18) Please provide your SAM.gov Unique Entity ID/Cage Code number. Buy America Compliance Respondents shall provide sufficient detail to determine compliance with the Buy American Act, including country of origin, domestic content, and availability of domestic alternatives. Responses should be complete and supported with verifiable information. Please identify the country of origin for the end product(s) being offered. Include the location of final assembly/manufacture. Please provide the percentage of domestic content (by cost) for each product(s). Describe the origin of the major components. Does your product qualify as a domestic end product in accordance with the Buy American Act? If the proposed product is not compliant, are you able to provide a BAA-compliant domestic alternative? Please identify the manufacturer name and location for the product(s). Confirm whether the manufacturer is U.S.-based. Identify the country of origin of each product and indicate whether the product qualifies as a U.S.-made or designated-country end product in accordance with the Trade Agreements Act Responses to this notice shall be submitted via email to wilbert.parks@va.gov. Telephone responses will not be accepted. Responses must be received no later than Friday, October 9, 2024 by 4:00 PM EST. All responses to this Sources Sought/RFI will be used for planning purposes only. Responses to this Sources Sought Notice / RFI are not considered a request to be added to a prospective bidders list or to receive a copy of the solicitation. If further RFIs and/or a solicitation or other announcement is issued as a result of the information provided from this RFI, all interested parties must respond to the specific posting separately IAW the specifications of that announcement. | 73% | Market Research | 10/21/2026 |
Additional Details
Solicitation Number
36C26226Q1223
Archive Date
Jul 30, 2026
Office Address
Gilbert, AZ, 85297